Potential Strategic Acquisitions to Strengthen Vertical Integration and Expand Distribution Capabilities NINGDE, China, July 28, 2025 (GLOBE NEWSWIRE) — Oriental Rise Holdings Limited (“Oriental Rise” or the “Company”) (NASDAQ: ORIS), an integrated tea supplier in mainland China, today announced that it has entered into a non-binding letter of intent (“LOI”) to acquire 100 percent of the equity interests of Fujian Daohe Tea Technology Co., Ltd. (“Daohe”) and Ningde Minji Tea Co., Ltd. (“Minji,” and together with Daohe, the “Targets”), both leading tea distributors in China. The LOI marks a significant step in Oriental Rise’s strategy to expand and diversify its portfolio within China’s fast-growing consumer goods and wellness sectors. The Company will now begin comprehensive due diligence on the Targets and work toward negotiating...

New York, July 28, 2025 (GLOBE NEWSWIRE) — On July 25, 2025, Inception Growth Acquisition Limited (the “Company”), a blank check company, previously announced that it convened its special meeting (“Special Meeting”) and immediately adjourned the Special Meeting, without conducting any business, to August 8, 2025. The Special Meeting was adjourned as to all of the proposals contained in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on May 27, 2025, as supplemented by the supplement to the definitive proxy statement on June 26, 2025 (the “Proxy Statement”), including the proposal to approve the proposed business combination with AgileAlgo Holdings Ltd. Redemption Deadline Extended The Company would like to further clarify that as a result of the adjournment, the deadline for delivery...

ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) (“Supernus“, and the “Company”), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act“), with respect to Supernus’ proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (NASDAQ: SAGE) (“Sage“), expired at 11:59 p.m. Eastern Time on July 25, 2025. On June 13, 2025, Supernus and Sage, entered into an Agreement and Plan of Merger (the “Merger Agreement“), by and among Supernus, Sage and Saphire, Inc., a Delaware corporation and a wholly owned subsidiary of Supernus (“Purchaser“). On June 25, 2025 and June 30, 2025, Supernus and Sage, respectively,...

MOUNT VERNON, Wash., July 28, 2025 (GLOBE NEWSWIRE) — Savi Financial Corporation, Inc. (OTC Pink: SVVB) (“Savi Financial” or the “Company”) and its wholly owned subsidiary, SaviBank, today announced that all parties have received final regulatory approval to complete the acquisition of SaviBank’s operating assets and the assumption of SaviBank’s deposits by Tacoma-based Harborstone Credit Union. The acquisition was announced on March 21, 2024, upon the parties’ entry into a Purchase and Assumption Agreement on that date. “We are delighted to have received our final approvals to allow the transaction to proceed to closing,” stated Michal D. Cann, Chairman and President of Savi Financial Corporation. “Although regulatory approval has taken longer than we had hoped, we are enthusiastic in that the approvals are not subject to any...

AMG to invest in Montefiore, a leading European private equity firm with €5 billion in AUM, focused on the services sector  Montefiore has a 20-year track record of consistently delivering top-tier returns by leveraging its differentiated strategy, sector expertise, unique sourcing capability, and value-creation skills   Montefiore’s management will retain a substantial majority of the firm’s equity and continue to lead Montefiore as an independent firm, in line with AMG’s partnership approach   Partnership further diversifies AMG’s business and expands its participation in global private markets  WEST PALM BEACH, Fla. and PARIS, July 28, 2025 (GLOBE NEWSWIRE) — AMG, a strategic partner to leading independent investment management firms globally, today announced that it has entered into a definitive agreement to acquire a minority...

Combination creates a leading diversified Americas-focused precious metals company (All amounts expressed in Canadian dollars unless otherwise stated) TORONTO, July 28, 2025 (GLOBE NEWSWIRE) — Torex Gold Resources Inc. (“Torex”, the “Company”) (TSX:TXG) (OTCQX:TORXF) and Prime Mining Corp. (“Prime Mining”) (TSX: PRYM) (OTCQX: PRMNF) (Frankfurt: O4V3) are pleased to announce that they have entered into a definitive agreement (the “Arrangement Agreement”) whereby Torex will acquire all of the issued and outstanding common shares of Prime Mining (the “Prime Mining Shares”) pursuant to a plan of arrangement (the “Transaction”). The Transaction will result in Torex owning a 100% interest in Prime Mining’s multi-million ounce Los Reyes gold-silver project (“Los Reyes” or the “Los Reyes Project”). The Los Reyes Project is located in Mexico,...

TORONTO and FLIN FLON, Manitoba, July 28, 2025 (GLOBE NEWSWIRE) — McEwen Inc. (“McEwen”) (NYSE: MUX) (TSX:MUX) and Canadian Gold Corp. (“Canadian Gold”) (TSX-V:CGC) are pleased to announce that they have entered into a binding letter of intent (the “LOI“) on July 27, 2025 in respect of a proposed transaction (the “Proposed Transaction“), whereby McEwen would acquire all of the issued and outstanding securities of Canadian Gold by way of plan of arrangement. If the Proposed Transaction is completed, Canadian Gold would become a wholly-owned subsidiary of McEwen. Canadian Gold’s principal asset is its 100% interest in the Tartan Mine, which is located in Manitoba, Canada (the “Tartan Mine“). The Tartan Mine is a high-grade former producing mine with existing infrastructure and high exploration...

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) —  Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, today announced the completion of its previously announced merger with Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”). The combined company...

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) — Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, today announced the completion of its previously announced merger with Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”). The combined company...

IRVINE, Calif., July 25, 2025 (GLOBE NEWSWIRE) — Apple iSports (OTC-QB: AAPI) (“Company” or “Apple iSports” or “AiS”), a gaming, entertainment, and technology services company, is pleased to announce it has signed a Definitive Agreement with LBC Enterprises Pty Ltd (“LBC” or “Lucky Bet”), an online gaming, wagering, and payment systems company. Key HighlightsLBC Enterprises Pty Ltd, a Queensland, Australia corporation, will sell all its shares to Apple iSports. The Board of Directors of both LBC and Apple iSports have unanimously approved the proposed transaction, which is expected to close in the third quarter of 2025, subject to any regulatory approvals and the satisfaction of closing conditions in the Definitive Agreement. LBC will continue to operate under its brand and will be led by Mr. Ian Parke, the CEO of LBC. Messrs....